This Article Full Text Full Text (PDF) All Versions of this Article: 2006-0034OCv1 35/6/722    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takeda, N. Articles by Kume, H. Search for Related Content PubMed PubMed Citation Articles by Takeda, N. Articles by Kume, H.

Role of RhoA Inactivation in Reduced Cell Proliferation of Human Airway Smooth Muscle by Simvastatin

Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

Correspondence and requests for reprints should be addressed to Hiroaki Kume, M.D., Ph.D., Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. E-mail: hkume{at}med.nagoya-u.ac.jp

Enhanced proliferation of smooth muscle cells contributes to airway remodeling of bronchial asthma. Recently, statins, inhibitors of 3-hydroxy-3-methylglutaryl–coenzyme A reductase, have been shown to inhibit proliferation of both vascular and airway smooth muscle cells independently of lowering cholesterol. However, the mechanisms remain to be elucidated. The purpose of this study was to determine molecular processes by which statins inhibit proliferation of human bronchial smooth muscle cells. Simvastatin (0.1–1.0 µM) significantly inhibited cell proliferation and DNA synthesis induced by FBS in a concentration-dependent manner. The inhibitory effects of simvastatin were antagonized by mevalonate and geranylgeranylpyrophosphate, whereas the effects were not affected by squalene and farnesylpyrophosphate. The antiproliferative effects of simvastatin were mimicked by GGTI-286, a geranylgeranyltransferase-I inhibitor, C3 exoenzyme, an inhibitor of Rho, and Y-27632, an inhibitor of Rho-kinase, a target protein of RhoA. Western blot analysis showed that the level of membrane localization of RhoA (active Rho) was markedly increased by FBS, and that the level of active RhoA increased by FBS was reduced by simvastatin. Moreover, the inhibitory effect of simvastatin on FBS-induced RhoA activation was also antagonized by geranylgeranylpyrophosphate, but not by farnesylpyrophosphate. Because these isoprenoids are required for prenylation of small G proteins RhoA and Ras, respectively, the present results demonstrate that an inhibition in airway smooth muscle cell proliferation by simvastatin is due to prevention of geranylgeranylation of RhoA, not farnesylation of Ras. Therefore, statins may have therapeutic potential for prohibiting airway remodeling in bronchial asthma.

Key Words: asthma • airway remodeling • 3-hydroxy-3-methylglutaryl–coenzyme A reductase inhibitors (statins) • Rho-kinase • isoprenoids

CLINICAL RELEVANCE Cell proliferation of airway smooth muscle is suppressed by RhoA/Rho-kinase inactivation regulated by the mevalonate pathways in cholesterol synthesis. Statins may be a novel therapeutic agent for prohibiting airway remodeling via these processes.

 

This article has been cited by other articles:

				Y. Chiba, S. Sato, M. Hanazaki, H. Sakai, and M. Misawa Inhibition of geranylgeranyltransferase inhibits bronchial smooth muscle hyperresponsiveness in mice Am J Physiol Lung Cell Mol Physiol, November 1, 2009; 297(5): L984 - L991. [Abstract] [Full Text] [PDF]

				A. A. Zeki, L. Franzi, J. Last, and N. J. Kenyon Simvastatin Inhibits Airway Hyperreactivity: Implications for the Mevalonate Pathway and Beyond Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 731 - 740. [Abstract] [Full Text] [PDF]

				H. Li, C. Y. Ung, X. H. Ma, B. W. Li, B. C. Low, Z. W. Cao, and Y. Z. Chen Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1 Bioinformatics, February 1, 2009; 25(3): 358 - 364. [Abstract] [Full Text] [PDF]

				J. E. Mallinson, D. Constantin-Teodosiu, J. Sidaway, F. R. Westwood, and P. L. Greenhaff Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy J. Physiol., January 1, 2009; 587(1): 219 - 230. [Abstract] [Full Text] [PDF]

				E J Hothersall, R Chaudhuri, C McSharry, I Donnelly, J Lafferty, A D McMahon, C J Weir, J Meiklejohn, N Sattar, I McInnes, et al. Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma Thorax, December 1, 2008; 63(12): 1070 - 1075. [Abstract] [Full Text] [PDF]

				C. J. Delvecchio, P. Bilan, P. Nair, and J. P. Capone LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1 Am J Physiol Lung Cell Mol Physiol, November 1, 2008; 295(5): L949 - L957. [Abstract] [Full Text] [PDF]

				S. Ito, H. Kume, K. Naruse, M. Kondo, N. Takeda, S. Iwata, Y. Hasegawa, and M. Sokabe A Novel Ca2+ Influx Pathway Activated by Mechanical Stretch in Human Airway Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 407 - 413. [Abstract] [Full Text] [PDF]

				W. T. Gerthoffer Migration of Airway Smooth Muscle Cells Proceedings of the ATS, January 1, 2008; 5(1): 97 - 105. [Abstract] [Full Text] [PDF]

				L. B. Fernandes, P. J. Henry, and R. G. Goldie Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 25 - 33. [Abstract] [PDF]